NCT04356170已完成2 期
A Phase II Randomized Trial, Non Comparative, Evaluating Chemotherapy Associated Cisplatin, 5-fluorouracil and Docetaxel at Adapted Doses in Patients With Locally Advanced Squamous Cell Carcinoma
Groupe Oncologie Radiotherapie Tete et Cou1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2021年2月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 105
- 试验地点
- 1
- 主要终点
- Efficacity of combination of TPFm
研究概览
简要总结
The objective of this study is to evaluate the efficacity of the combination of cisplatin-5-FU and docetaxel in adapted doses in term of response to treatment without toxicity
.
详细描述
After explaining the treatment modalities, having read and explained the information letter to them, patients who have signed the consent to participate in the trial and who meet the inclusion criteria will be enrolled and randomized in the trial .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven squamous cell carcinoma of the head and neck from one or more of the following primary sites: oral cavity, oropharynx, hypopharynx or larynx, lymphadenopathy without front door
- •Inoperable tumor or tumor whose surgery would be multilating.
- •The non-operability criteria are:
- •Technically impossible resection: fixation / invasion of the tumor at the base of the skull or at the cervical vertebrae, nasopharynx involved, lymph nodes
- •Medical selection based on low surgical curability. This category includes all T3-T4 and all N2-N3 (AJCC 8th edition, June 2018)
- •Medical selection based on an organ preservation strategy
- •Patient not previously treated for ORL cancer
- •Age > 18 and < 75 years
- •PS 0 or 1 according to WHO
- •At least one lesion measurable according to the RECIST 1.1 criteria
- •Patient who can receive TPF according to the following criteria:
- •Adequate hematological function: neutrophils ³ 1.5 x 109 / l, platelets *100 x 109 / l, hemoglobin 10 g / dl (or 6.2 mmol / l)
- •Adequate renal function: calculated creatinine clearance (Cockroft & Gault) or measured ³ 60 ml / min.
- •Adequate liver function: normal total bilirubin; ASAT and ALAT less than or equal to 1.5 ´ LNS; PAL less than or equal to 2.5 X LNS
- •Grade <2 peripheral neuropathy according to NCI CTCAE v5.0
- •No clinical impairment of hearing function
- •For patients aged 71 to 74, PS at 0 and considered non-geriatrically fragile (G8 questionnaire and multidimensional assessments proposed by the GERICO group (ADL, MMSE, GDS scale, nutrition, motor skills and balance, geographic and personal situation and assessments) thymic))
- •Estimated life expectancy greater than or equal to 3 months
- •Weight loss of less than 10% during the 3 months before randomization
- •Patient understanding French and able to complete quality of life questionnaires
- •Patient having given written consent before any specific protocol procedure
- •Affiliation to a social security scheme or beneficiary of such a scheme
- •Women of childbearing potential and sexually active men agreeing to use effective contraceptive methods for the duration of treatment and at least 6 months after the last administration of study treatments
- •Patient agrees not to donate sperm for the duration of the treatment and at least 6 months after the last administration of the study treatments
- •Absence of deficiency in dihydropyrimidine dehydrogenase activity determined by uracilemia assay (Uracilemia < 16 ng/mL)
排除标准
- •Cancers of the nasopharynx, sinuses or nasal cavities, and any histology other than squamous cell carcinoma
- •Vaccination against recent or planned yellow fever
- •Known deficiency in dihydropyrimidine dehydrogenase (DPD) or determined by the determination of uricemia.
- •History of other cancer except in situ cervical cancer or controlled basal cell carcinoma. Patients in remission from cancer treated more than 3 years ago are eligible. Patients treated by surgery alone for ORL cancer in the previous 3 years are eligible.
- •Previous treatment of an ORL cancer by chemotherapy or radiotherapy. Patients treated by surgery alone for ORL cancer in the previous 3 years are eligible).
- •Presence of distant metastasis.
- •Participation in a therapeutic trial in the 30 days preceding randomization
- •Concomitant anticancer treatment
- •Patient under chronic treatment (3 months) with corticosteroid whose daily dosage is 10 mg / day of methylprednisolone or equivalent
- •Other existing serious medical pathologies (non-exhaustive list):
- •Uncontrolled cardiac pathology despite adequate treatment
- •Myocardial infarction in the 6 months preceding randomization
- •Neurological or psychiatric history such as dementia, convulsions
- •Active infection
- •Significant gastrointestinal abnormalities, including those that require parenteral nutrition, active peptic ulcer, and history of surgeries affecting absorption
- •Obstructive pulmonary disease requiring hospitalization in the year preceding randomization
- •Uncontrolled type II diabetes or other corticosteroid contraindications.
- •Moderate or severe eczema
- •Known hypersensitivity to docetaxel, cisplatin 5FU or one of their excipients.
- •Intended concomitant use of phenytoin, carbamazepine, barbiturates or rifampicin
- •Presence, upon selection, of psychological, family, social or geographic factors likely to influence the patient's compliance with the study and monitoring protocol.
- •Pregnant or lactating woman
- •Patient (male or female) of reproductive age who is unable or unwilling to take adequate contraceptive measures during treatment and up to 6 months after the last treatment is administered.
- •Persons deprived of their liberty, under guardianship or curatorship
研究组 & 干预措施
TPF (docetaxel, cisplatine, 5-FU)
Active Comparator
Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
干预措施: Docetaxel (Drug)
TPF (docetaxel, cisplatine, 5-FU)
Active Comparator
Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
干预措施: Cisplatin (Drug)
TPF (docetaxel, cisplatine, 5-FU)
Active Comparator
Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
干预措施: Fluoro Uracil (Drug)
TPFm (docetaxel, cisplatine, 5-FU) modifié
Experimental
Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
干预措施: Docetaxel (Drug)
TPFm (docetaxel, cisplatine, 5-FU) modifié
Experimental
Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
干预措施: Cisplatin (Drug)
TPFm (docetaxel, cisplatine, 5-FU) modifié
Experimental
Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
干预措施: Fluoro Uracil (Drug)
结局指标
主要结局
Efficacity of combination of TPFm
时间窗: 8 weeks after the end of treatment
Success rate of patients at 8 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric CancerGastric CancerGastroesophageal Junction CancerNCT01743365Hellenic Cooperative Oncology Group55
已完成
1 期
Phase I/II trial of 5-FU, cisplatin, and weekly paclitaxel in patients with esophageal cancerEsophageal cancerJPRN-UMIN000013627ippon Medical School Musashi Kosugi Hospital47
已完成
2 期
An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic DiseaseSquamous Cell Carcinoma of the AnusCancer - Bowel - AnalACTRN12616000061437Australasian Gastro-Intestinal Trials Group (AGITG)91
招募中
2 期
Randomized phase II trial of UFT plus Cisplatin versus Pemetrexed plus Cisplatin combined with Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer. North Japan Lung Cancer Study Group Trial 1001 (NJLCG1001)non-small-cell lung cancerJPRN-UMIN000003948Miyagi Cancer Center84
进行中（未招募）
1 期
A Phase II Trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic carcinoma of the penis - Penile TPFocally advanced and metastatic carcinoma of the penisMedDRA version: 13.1Level: LLTClassification code 10034299Term: Penile cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000707-28-GBThe Institute of Cancer Research29